Symbol="NRIX"
AssetType="Common Stock"
Name="Nurix TherapeuticsÂ Inc"
Description="Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company is headquartered in San Francisco, California."
CIK="1549595"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="1700 OWENS STREET, SUITE 205, SAN FRANCISCO, CA, US"
FiscalYearEnd="November"
LatestQuarter="2023-05-31"
MarketCapitalization="410183000"
EBITDA="-159600992"
PERatio="None"
PEGRatio="None"
BookValue="5.46"
DividendPerShare="0"
DividendYield="0"
EPS="-2.99"
RevenuePerShareTTM="1.144"
ProfitMargin="-2.584"
OperatingMarginTTM="-2.71"
ReturnOnAssetsTTM="-0.277"
ReturnOnEquityTTM="-0.598"
RevenueTTM="60935000"
GrossProfitTTM="-145870000"
DilutedEPSTTM="-2.99"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="1.683"
AnalystTargetPrice="27.25"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="14.31"
PriceToBookRatio="1.701"
EVToRevenue="6.41"
EVToEBITDA="-1.536"
Beta="1.612"
num_52WeekHigh="16.81"
num_52WeekLow="8.22"
num_50DayMovingAverage="9.55"
num_200DayMovingAverage="10.47"
SharesOutstanding="48200100"
DividendDate="None"
ExDividendDate="None"
symbol="NRIX"
open="8.54"
high="8.77"
low="8.34"
price="8.62"
volume="318345.00"
latest_trading_day="2023-08-28"
previous_close="8.51"
change="0.11"
change_percent="1.2926%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="28"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="72"
Volume_recent_avg="315111"
Change_recent_avg="-0.01"
Delta_recent_avg="0.62"
Variance_recent_avg="0.31"
Change_ratio_recent_avg="-0.19"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="72"
Aroon_momentum_negative="28"
image_negative_thumbnail_id_1="156"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0020.jpeg"
image_negative_thumbnail_id_2="117"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0059.jpeg"
image_neutral_thumbnail_id_1="551"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0048.jpeg"
image_neutral_thumbnail_id_2="527"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0072.jpeg"
image_positive_thumbnail_id_1="650"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0058.jpeg"
image_positive_thumbnail_id_2="1003"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0165.jpeg"
image_professor_thumbnail_id_1="1180"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0014.jpeg"
image_professor_thumbnail_id_2="1193"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0027.jpeg"
